623 related articles for article (PubMed ID: 18296124)
1. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.
Dichgans M; Markus HS; Salloway S; Verkkoniemi A; Moline M; Wang Q; Posner H; Chabriat HS
Lancet Neurol; 2008 Apr; 7(4):310-8. PubMed ID: 18296124
[TBL] [Abstract][Full Text] [Related]
2. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
3. Donepezil for dementia due to Alzheimer's disease.
Birks JS; Harvey RJ
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
[TBL] [Abstract][Full Text] [Related]
4. Cholinesterase inhibitors for rarer dementias associated with neurological conditions.
Li Y; Hai S; Zhou Y; Dong BR
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD009444. PubMed ID: 25734590
[TBL] [Abstract][Full Text] [Related]
5. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
Wilkinson D; Windfeld K; Colding-Jørgensen E
Lancet Neurol; 2014 Nov; 13(11):1092-1099. PubMed ID: 25297016
[TBL] [Abstract][Full Text] [Related]
7. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T
Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial.
Black S; Román GC; Geldmacher DS; Salloway S; Hecker J; Burns A; Perdomo C; Kumar D; Pratt R;
Stroke; 2003 Oct; 34(10):2323-30. PubMed ID: 12970516
[TBL] [Abstract][Full Text] [Related]
10. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease: A multicentre, randomized, double-blind, placebo-controlled trial.
Jia J; Wei C; Liang J; Zhou A; Zuo X; Song H; Wu L; Chen X; Chen S; Zhang J; Wu J; Wang K; Chu L; Peng D; Lv P; Guo H; Niu X; Chen Y; Dong W; Han X; Fang B; Peng M; Li D; Jia Q; Huang L
Alzheimers Dement; 2016 Feb; 12(2):89-99. PubMed ID: 26086183
[TBL] [Abstract][Full Text] [Related]
11. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
[TBL] [Abstract][Full Text] [Related]
12. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
Frölich L; Ashwood T; Nilsson J; Eckerwall G;
J Alzheimers Dis; 2011; 24(2):363-74. PubMed ID: 21258153
[TBL] [Abstract][Full Text] [Related]
13. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.
Johannsen P; Salmon E; Hampel H; Xu Y; Richardson S; Qvitzau S; Schindler R;
CNS Drugs; 2006; 20(4):311-25. PubMed ID: 16599649
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
15. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials.
Román GC; Wilkinson DG; Doody RS; Black SE; Salloway SP; Schindler RJ
Dement Geriatr Cogn Disord; 2005; 20(6):338-44. PubMed ID: 16192723
[TBL] [Abstract][Full Text] [Related]
16. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.
Salloway S; Ferris S; Kluger A; Goldman R; Griesing T; Kumar D; Richardson S;
Neurology; 2004 Aug; 63(4):651-7. PubMed ID: 15326237
[TBL] [Abstract][Full Text] [Related]
18. Donepezil for mild cognitive impairment.
Birks J; Flicker L
Cochrane Database Syst Rev; 2006 Jul; (3):CD006104. PubMed ID: 16856114
[TBL] [Abstract][Full Text] [Related]
19. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
Rogers SL; Doody RS; Mohs RC; Friedhoff LT
Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
[TBL] [Abstract][Full Text] [Related]
20. Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study.
Mazeh D; Zemishlani H; Barak Y; Mirecki I; Paleacu D
Int Psychogeriatr; 2006 Sep; 18(3):429-36. PubMed ID: 16478570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]